NO20023780L - Dipeptid nitril katepsin K inhibitorer - Google Patents

Dipeptid nitril katepsin K inhibitorer

Info

Publication number: NO20023780L
Authority: NO; Norway
Prior art keywords: inhibitors; dipeptide nitrile; nitrile cathepsin; cathepsin; dipeptide
Prior art date: 2000-02-10

Application number

NO20023780A

Other languages

English (en)

Other versions

NO20023780D0 (no

Inventor

Martin Missbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2002-08-09

Publication date

2002-08-09

2002-08-09 Application filed by Novartis Ag filed Critical Novartis Ag

2002-08-09 Publication of NO20023780D0 publication Critical patent/NO20023780D0/no

2002-08-09 Publication of NO20023780L publication Critical patent/NO20023780L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20023780A 2000-02-10 2002-08-09 Dipeptid nitril katepsin K inhibitorer NO20023780L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0003111.2A GB0003111D0 (en)	2000-02-10	2000-02-10	Organic compounds
PCT/EP2001/001359 WO2001058886A1 (en)	2000-02-10	2001-02-08	Dipeptide nitrile cathepsin k inhibitors

Publications (2)

Publication Number	Publication Date
NO20023780D0 NO20023780D0 (no)	2002-08-09
NO20023780L true NO20023780L (no)	2002-08-09

Family

ID=9885359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023780A NO20023780L (no)	2000-02-10	2002-08-09	Dipeptid nitril katepsin K inhibitorer

Country Status (30)

Country	Link
US (4)	US6642239B2 (no)
EP (1)	EP1254124B1 (no)
JP (1)	JP3942895B2 (no)
KR (1)	KR100544553B1 (no)
CN (2)	CN1636980A (no)
AR (1)	AR029466A1 (no)
AT (1)	ATE402930T1 (no)
AU (1)	AU764334B2 (no)
BR (1)	BR0108118A (no)
CA (1)	CA2396158C (no)
CO (1)	CO5261578A1 (no)
CZ (1)	CZ20022721A3 (no)
DE (1)	DE60135087D1 (no)
ES (1)	ES2310177T3 (no)
GB (1)	GB0003111D0 (no)
HU (1)	HUP0300148A3 (no)
IL (1)	IL150406A0 (no)
MX (1)	MXPA02007768A (no)
MY (1)	MY122826A (no)
NO (1)	NO20023780L (no)
NZ (1)	NZ519940A (no)
PE (1)	PE20020220A1 (no)
PL (1)	PL200119B1 (no)
PT (1)	PT1254124E (no)
RU (2)	RU2265601C2 (no)
SK (1)	SK11462002A3 (no)
TR (1)	TR200201752T2 (no)
TW (1)	TWI258473B (no)
WO (1)	WO2001058886A1 (no)
ZA (1)	ZA200206218B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9723407D0 (en) *	1997-11-05	1998-01-07	Ciba Geigy Ag	Organic compounds
HRP20010738B1 (en)	1999-03-15	2005-02-28	Axys Pharmaceuticals	N-cyanomethyl amides as protease inhibitors
GB0003111D0 (en) *	2000-02-10	2000-03-29	Novartis Ag	Organic compounds
US7199102B2 (en) *	2000-08-24	2007-04-03	The Regents Of The University Of California	Orally administered peptides synergize statin activity
US7148197B2 (en) *	2000-08-24	2006-12-12	The Regents Of The University Of California	Orally administered small peptides synergize statin activity
US7723303B2 (en) *	2000-08-24	2010-05-25	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7030116B2 (en)	2000-12-22	2006-04-18	Aventis Pharmaceuticals Inc.	Compounds and compositions as cathepsin inhibitors
EP1383748A2 (en)	2000-12-22	2004-01-28	Axys Pharmaceuticals, Inc.	Novel compounds and compositions as cathepsin inhibitors
CA2460125A1 (en)	2001-09-14	2003-03-27	Aventis Pharmaceuticals Inc.	Novel compounds and compositions as cathepsin inhibitors
KR20050044497A (ko)	2001-11-14	2005-05-12	아벤티스 파마슈티칼스 인크.	올리고펩티드 및 카텝신 ｓ 억제제로서 이를 포함하는조성물
WO2003075836A2 (en) *	2002-03-05	2003-09-18	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
AU2003298740A1 (en) *	2002-12-05	2004-06-30	Axys Pharmaceuticals, Inc.	Cyanomethyl derivatives as cysteine protease inhibitors
US7405229B2 (en) *	2003-06-30	2008-07-29	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
WO2005014006A1 (en) *	2003-07-21	2005-02-17	Novartis Ag	Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
WO2005049028A1 (en) *	2003-11-19	2005-06-02	Novartis Ag	Use of cathepsin k inhibitors in severe bone loss diseases
BRPI0506719A (pt)	2004-01-08	2007-05-02	Medivir Ab	composto, composição farmacêutica, e, uso de um composto
US20060205669A1 (en) *	2004-09-16	2006-09-14	The Regents Of The University Of California	G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
RU2414236C2 (ru)	2004-12-06	2011-03-20	Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье	Способ улучшения структуры и/или функций артериол
GB0427380D0 (en) *	2004-12-14	2005-01-19	Novartis Ag	Organic compounds
WO2006076796A1 (en) *	2005-01-19	2006-07-27	Merck Frosst Canada Ltd.	Cathepsin k inhibitors and obesity
WO2006076797A1 (en) *	2005-01-19	2006-07-27	Merck Frosst Canada Ltd.	Cathepsin k inhibitors and atherosclerosis
US20080293639A1 (en) *	2005-04-29	2008-11-27	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GB0517637D0 (en) *	2005-08-30	2005-10-05	Novartis Ag	Organic compounds
AU2007205578B2 (en)	2006-01-11	2012-06-28	Seikagaku Corporation	Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP4047365B2 (ja)	2006-01-11	2008-02-13	生化学工業株式会社	シクロアルカンカルボキサミド誘導体及びその製造方法
JP3975226B2 (ja) *	2006-01-11	2007-09-12	生化学工業株式会社	シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
WO2007137149A2 (en) *	2006-05-22	2007-11-29	Velcura Therapeutics, Inc.	Use of cathepsin k antagonists in bone production
GB0614044D0 (en) *	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
GB0614046D0 (en)	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
GB0614053D0 (en) *	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
US20110092484A1 (en)	2007-06-08	2011-04-21	Nippon Chemiphar Co., Ltd.	Therapeutic or prophylactic agent for cerebral aneurysm
BRPI0702541A2 (pt)	2007-06-21	2009-02-10	Petroleo Brasileiro Sa	processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas
US7893067B2 (en)	2007-06-27	2011-02-22	Medivir Ab	Cysteine protease inhibitors
EP2216047A4 (en) *	2007-10-24	2011-12-28	Nat Univ Corp Tokyo Med & Dent	Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
WO2009076490A1 (en) *	2007-12-12	2009-06-18	Velcura Therapeutics, Inc.	Use of cathepsin l antagonists in the treatment of bone disease
EP2719700A1 (en)	2008-01-09	2014-04-16	Amura Therapeutics Limited	Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
WO2009103432A2 (en) *	2008-02-21	2009-08-27	Sanofi-Aventis	Covalently binding imaging probes
GB0817425D0 (en) *	2008-09-24	2008-10-29	Medivir Ab	Protease inhibitors
US20100298507A1 (en)	2009-05-19	2010-11-25	Menschig Klaus R	Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby
JP6000340B2 (ja)	2011-05-16	2016-09-28	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	肺高血圧症および／または心不全の治療および／または予防のためのカテプシンｋ阻害の使用
EP2537532A1 (en)	2011-06-22	2012-12-26	J. Stefan Institute	Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
US9593138B2 (en)	2012-10-05	2017-03-14	Wayne State University	Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
WO2014199644A1 (ja)	2013-06-14	2014-12-18	生化学工業株式会社	α－オキソアシルアミノカプロラクタム誘導体
EP3009425B1 (en)	2013-06-14	2018-06-06	Seikagaku Corporation	Alpha-oxoacylaminocaprolactam

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3467691A (en)	1964-04-22	1969-09-16	Tsutomu Irikura	N-(n-acylaminoacyl)-aminoacetonitriles
US5206249A (en)	1991-03-27	1993-04-27	Du Pont Merck Pharmaceutical Company	Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
EP0547699A1 (en)	1991-12-19	1993-06-23	Merck & Co. Inc.	Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3283114B2 (ja)	1992-09-07	2002-05-20	クミアイ化学工業株式会社	縮合ヘテロ環誘導体及び農園芸用殺菌剤
JP2848232B2 (ja)	1993-02-19	1999-01-20	武田薬品工業株式会社	アルデヒド誘導体
DE69406083T2 (de)	1993-04-28	1998-02-26	Ihara Chemical Ind Co	Aminosäureamide, bakterizide für gartenbau und landwirtschaft sowie herstellungverfahren
WO1995003794A1 (en) *	1993-07-30	1995-02-09	Smithkline Beecham Corporation	3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates
JPH09504302A (ja)	1993-11-01	1997-04-28	日本チバガイギー株式会社	エンドセリン・レセプター・アンタゴニスト
US5486623A (en) *	1993-12-08	1996-01-23	Prototek, Inc.	Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) *	1994-02-25	1995-05-26	Khepri Pharmaceuticals Inc	Novel cysteine protease inhibitors
PT749418E (pt)	1994-03-10	2001-01-31	Searle & Co	Derivados de l-n6-(1-iminoetil)lisina uteis como inibidores de oxido nitrico sintetase
US5614649A (en) *	1994-11-14	1997-03-25	Cephalon, Inc.	Multicatalytic protease inhibitors
US5804560A (en)	1995-01-06	1998-09-08	Sibia Neurosciences, Inc.	Peptide and peptide analog protease inhibitors
CA2218716A1 (en) *	1995-04-21	1996-10-24	Novartis Ag	N-aroylamino acid amides as endothelin inhibitors
WO1997027200A1 (en)	1996-01-26	1997-07-31	Smithkline Beecham Plc	Thienoxazinone derivatives useful as antiviral agents
AU3359697A (en)	1996-07-08	1998-02-02	Yamanouchi Pharmaceutical Co., Ltd.	Bone resorption inhibitors
IL129504A0 (en)	1996-11-22	2000-02-29	Elan Pharm Inc	N-(aryl/heteroaryl/alkylacetyl) amino acid amides pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
HUP0004400A3 (en)	1997-11-05	2002-10-28	Novartis Ag	Dipeptide nitriles, process for their preparation, pharmaceutical compositions comprising thereof and their use
GB9723407D0 (en) *	1997-11-05	1998-01-07	Ciba Geigy Ag	Organic compounds
US6355678B1 (en) *	1998-06-29	2002-03-12	Parker Hughes Institute	Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
AU2560000A (en)	1999-02-20	2000-09-04	Astrazeneca Ab	Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
WO2000049007A1 (en)	1999-02-20	2000-08-24	Astrazeneca Ab	Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
CA2360740A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
HRP20010738B1 (en) *	1999-03-15	2005-02-28	Axys Pharmaceuticals	N-cyanomethyl amides as protease inhibitors
US6420364B1 (en) *	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
JP2003509410A (ja) *	1999-09-16	2003-03-11	アクシス・ファーマシューティカルズ・インコーポレイテッド	カテプシンインヒビターとしての化合物および薬学的組成物
JP2001139320A (ja) *	1999-11-05	2001-05-22	Asahi Glass Co Ltd	球状シリカゲルの製造方法
KR100468254B1 (ko) *	1999-12-24	2005-01-27	에프. 호프만-라 로슈 아게	카텝신 ｋ 억제제로서의 니트릴 유도체
DE60132975T2 (de) *	2000-01-06	2009-02-26	Merck Frosst Canada Inc., Kirkland	Neue substanzen und verbindungen als protease-inhibitoren
GB0003111D0 (en) *	2000-02-10	2000-03-29	Novartis Ag	Organic compounds

2000
- 2000-02-10 GB GBGB0003111.2A patent/GB0003111D0/en not_active Ceased
2001
- 2001-02-02 TW TW090102220A patent/TWI258473B/zh not_active IP Right Cessation
- 2001-02-06 MY MYPI20010514A patent/MY122826A/en unknown
- 2001-02-07 US US09/778,302 patent/US6642239B2/en not_active Expired - Fee Related
- 2001-02-08 CN CNA2004100909449A patent/CN1636980A/zh active Pending
- 2001-02-08 NZ NZ519940A patent/NZ519940A/en unknown
- 2001-02-08 ES ES01919270T patent/ES2310177T3/es not_active Expired - Lifetime
- 2001-02-08 PT PT01919270T patent/PT1254124E/pt unknown
- 2001-02-08 EP EP01919270A patent/EP1254124B1/en not_active Expired - Lifetime
- 2001-02-08 WO PCT/EP2001/001359 patent/WO2001058886A1/en not_active Ceased
- 2001-02-08 TR TR2002/01752T patent/TR200201752T2/xx unknown
- 2001-02-08 RU RU2002123350/04A patent/RU2265601C2/ru not_active IP Right Cessation
- 2001-02-08 RU RU2005108133/04A patent/RU2293732C2/ru active
- 2001-02-08 SK SK1146-2002A patent/SK11462002A3/sk not_active Application Discontinuation
- 2001-02-08 HU HU0300148A patent/HUP0300148A3/hu unknown
- 2001-02-08 PL PL357901A patent/PL200119B1/pl unknown
- 2001-02-08 KR KR1020027010280A patent/KR100544553B1/ko not_active Expired - Fee Related
- 2001-02-08 DE DE60135087T patent/DE60135087D1/de not_active Expired - Lifetime
- 2001-02-08 AT AT01919270T patent/ATE402930T1/de active
- 2001-02-08 BR BR0108118-7A patent/BR0108118A/pt not_active Application Discontinuation
- 2001-02-08 CA CA002396158A patent/CA2396158C/en not_active Expired - Fee Related
- 2001-02-08 MX MXPA02007768A patent/MXPA02007768A/es active IP Right Grant
- 2001-02-08 JP JP2001558437A patent/JP3942895B2/ja not_active Expired - Fee Related
- 2001-02-08 CZ CZ20022721A patent/CZ20022721A3/cs unknown
- 2001-02-08 AU AU46426/01A patent/AU764334B2/en not_active Ceased
- 2001-02-08 IL IL15040601A patent/IL150406A0/xx unknown
- 2001-02-08 CN CNB018048099A patent/CN1183122C/zh not_active Expired - Fee Related
- 2001-02-08 PE PE2001000139A patent/PE20020220A1/es not_active Application Discontinuation
- 2001-02-08 AR ARP010100563A patent/AR029466A1/es not_active Application Discontinuation
- 2001-02-12 CO CO01010168A patent/CO5261578A1/es not_active Application Discontinuation
2002
- 2002-08-05 ZA ZA200206218A patent/ZA200206218B/en unknown
- 2002-08-09 NO NO20023780A patent/NO20023780L/no unknown
2003
- 2003-04-09 US US10/410,377 patent/US20030203919A1/en not_active Abandoned
2005
- 2005-08-03 US US11/195,747 patent/US20050267129A1/en not_active Abandoned
2007
- 2007-04-23 US US11/738,878 patent/US20070191392A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PE20020220A1 (es)	2002-03-25
US20050267129A1 (en)	2005-12-01
EP1254124B1 (en)	2008-07-30
MY122826A (en)	2006-05-31
JP2003522764A (ja)	2003-07-29
SK11462002A3 (sk)	2003-01-09
IL150406A0 (en)	2002-12-01
JP3942895B2 (ja)	2007-07-11
KR20020072310A (ko)	2002-09-14
US20010016207A1 (en)	2001-08-23
KR100544553B1 (ko)	2006-01-24
AU764334B2 (en)	2003-08-14
TR200201752T2 (tr)	2002-10-21
CA2396158C (en)	2010-02-02
PL200119B1 (pl)	2008-12-31
GB0003111D0 (en)	2000-03-29
CA2396158A1 (en)	2001-08-16
MXPA02007768A (es)	2002-10-11
PL357901A1 (en)	2004-07-26
US20070191392A1 (en)	2007-08-16
NO20023780D0 (no)	2002-08-09
ES2310177T3 (es)	2009-01-01
CN1183122C (zh)	2005-01-05
HUP0300148A2 (en)	2003-05-28
RU2293732C2 (ru)	2007-02-20
HK1050197A1 (en)	2003-06-13
NZ519940A (en)	2004-02-27
ATE402930T1 (de)	2008-08-15
CZ20022721A3 (cs)	2002-11-13
AR029466A1 (es)	2003-07-02
US6642239B2 (en)	2003-11-04
AU4642601A (en)	2001-08-20
CO5261578A1 (es)	2003-03-31
RU2002123350A (ru)	2004-01-10
DE60135087D1 (de)	2008-09-11
PT1254124E (pt)	2008-11-03
RU2265601C2 (ru)	2005-12-10
TWI258473B (en)	2006-07-21
EP1254124A1 (en)	2002-11-06
CN1398260A (zh)	2003-02-19
RU2005108133A (ru)	2006-09-10
ZA200206218B (en)	2003-08-05
US20030203919A1 (en)	2003-10-30
HUP0300148A3 (en)	2005-04-28
CN1636980A (zh)	2005-07-13
WO2001058886A1 (en)	2001-08-16
BR0108118A (pt)	2003-02-25

Publication	Publication Date	Title
NO20023780L (no)	2002-08-09	Dipeptid nitril katepsin K inhibitorer
EP1272467A4 (en)	2003-05-07	Cathepsin cysteine protease inhibitors
CY2012007I2 (el)	2014-07-02	Πεπτιδομιμητικοι αναστολεις πρωτεασης
NO20026283L (no)	2003-02-28	Inhibitorer av kobberholdige aminosydaser
NO20034044D0 (no)	2003-09-12	Metallproteinase-inhibitorer
ATE524441T1 (de)	2011-09-15	Vla-4-inhibitoren
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
DZ3318A1 (fr)	2001-09-27	Inhibiteur de proteinase
EE200300439A (et)	2003-12-15	Metalloproteinaasi inhibiitorid
EP1499336A4 (en)	2005-06-01	PROTEASE INHIBITORS
NO20034032L (no)	2003-11-10	Metallproteinase-inhibitorer
EP1694647A4 (en)	2010-08-04	CATHEPSINCYSTEINPROTEASEHEMMER
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20025786L (no)	2003-02-12	Protaseinhibitorer
NO20025005D0 (no)	2002-10-17	Proteaseinhibitorer
DE60132468D1 (de)	2008-03-06	Alen-lanosterol zyklase inhibitoren
NO20032328D0 (no)	2003-05-22	Proteaseinhibitorer
AR028075A1 (es)	2003-04-23	Inhibidores de la peptido-desformilasa
DE60124397D1 (de)	2006-12-21	Inhibitoren von serinproteasen